Physician profile
Anna Ivanenko
NPI 1255308334
$14,044.22
in general payments reported to CMS, 2019-2025
22 companies · $260 in 2025
The $260 reported for 2025 was less than what a typical Sleep Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $337).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $690 · 2020: $252 · 2021: $679 · 2022: $598 · 2023: $11K · 2024: $822 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,712 · Food and Beverage: $2,193 · Travel and Lodging: $921.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,711.50 |
| Food and Beverage | $2,192.52 |
| Travel and Lodging | $920.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $10,234.84 | 2019-2024 | |
| Tris Pharma INC | $860.74 | 2019-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Neos Therapeutics, Lp | $781.03 | 2019-2025 | Adzenys Xr-Odt |
| Ironshore Pharmaceuticals INC. | $640.11 | 2019-2024 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $353.56 | 2024-2025 | Caplyta |
| Corium, LLC | $237.12 | 2021-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $223.71 | 2021-2023 | Qelbree |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.61 | 2019-2022 | |
| Axsome Therapeutics, INC. | $94.06 | 2024 | Sunosi |
| Harmony Biosciences LLC | $88.81 | 2020-2023 | Wakix |
| Bayer Healthcare Pharmaceuticals INC. | $81.87 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $72.60 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $66.44 | 2019-2023 | Breztri |
| United Therapeutics Corporation | $36.46 | 2021 | |
| Mallinckrodt Hospital Products INC. | $28.17 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inogen, INC. | $23.88 | 2022 | |
| Grifols USA, LLC | $22.44 | 2021 | |
| Glaxosmithkline, LLC. | $21.90 | 2019 | |
| Sunovion Pharmaceuticals INC. | $21.11 | 2019 | |
| Ucb, INC. | $19.13 | 2019 | |
| Bausch Health US, LLC | $13.09 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Ivanenko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.